The Developmental Funds are used to promote strategic cancer-research initiatives that the Cancer Center Director and other senior Cancer Center members have deemed important for the overall success of Cold Spring Harbor Laboratory's cancer research program. An important use of these funds has been to support new faculty recruited to the Cancer Center and to promote development of new technologies, either within the research programs or in the Cancer Center Shared Resources. CSHL has a dynamic research environment with a relatively high turnover of faculty, compared to the traditional university model. This provides an opportunity to recruit outstanding young scientists at the beginning of their careers. The Developmental Funds are a critical component for this recruitment and have provided support for investigators who have gone on to establish vibrant and productive cancer-research programs. These investigators have been successful in obtaining independent funding to continue their research. An extremely valuable source of funding, the Developmental funds give the Cancer Center Director the flexibility to support novel projects and incorporate new technologies and approaches. This also significantly enhances the opportunity for investigators to pioneer new and exciting research directions. The Developmental Funds strengthen the Cancer Center initiatives by allowing the recruitment of additional new faculty, whose inventive research approaches complement and expand upon current cancer-research programs.
Developmental funds at the Cold Spring Harbor Laboratory are used primarily for recruitment of new faculty whose research can expand existing cancer research programs and move into new directions to promote the Cancer Center's mission to understand the underlying mechanisms of cancer as a means to developing strategies for therapeutic intervention.
|Chaudhary, Fauzia; Lucito, Robert; Tonks, Nicholas K (2015) Missing-in-Metastasis regulates cell motility and invasion via PTP?-mediated changes in SRC activity. Biochem J 465:89-101|
|Fan, Gaofeng; Wrzeszczynski, Kazimierz O; Fu, Cexiong et al. (2015) A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines. Biochem J 465:433-42|
|Streppel, M M; Lata, S; DelaBastide, M et al. (2014) Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 33:347-57|
|Jensen, Mads A; Wilkinson, John E; Krainer, Adrian R (2014) Splicing factor SRSF6 promotes hyperplasia of sensitized skin. Nat Struct Mol Biol 21:189-97|
|Chio, Iok In Christine; Yordanov, Georgi; Tuveson, David (2014) MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J Natl Cancer Inst 106:|
|Eckersley-Maslin, Mélanie A; Thybert, David; Bergmann, Jan H et al. (2014) Random monoallelic gene expression increases upon embryonic stem cell differentiation. Dev Cell 28:351-65|
|Schwertassek, Ulla; Haque, Aftabul; Krishnan, Navasona et al. (2014) Reactivation of oxidized PTP1B and PTEN by thioredoxin 1. FEBS J 281:3545-58|
|Yang, Ming; Haase, Astrid D; Huang, Fang-Ke et al. (2014) Dephosphorylation of tyrosine 393 in argonaute 2 by protein tyrosine phosphatase 1B regulates gene silencing in oncogenic RAS-induced senescence. Mol Cell 55:782-90|
|Bergmann, Jan H; Spector, David L (2014) Long non-coding RNAs: modulators of nuclear structure and function. Curr Opin Cell Biol 26:10-8|
|Miething, Cornelius; Scuoppo, Claudio; Bosbach, Benedikt et al. (2014) PTEN action in leukaemia dictated by the tissue microenvironment. Nature 510:402-6|
Showing the most recent 10 out of 120 publications